UCLA Researchers Develop Strategy to Overcome Prostate Cancer Treatment Resistance

UCLA researchers identified that combining antibody-drug conjugates with a BCL-XL protein-blocking drug significantly increases cancer cell death in metastatic castration-resistant prostate cancer models.

The study, published in the Journal of Clinical Investigation, found that targeting proteins B7-H3, PSMA, and STEAP1 simultaneously with complementary drug payloads improves therapeutic efficacy compared to single-agent treatments.

Laboratory and animal tests showed the combination therapy slowed tumor growth more effectively, particularly in tumors with an intact TP53 gene, offering a potential framework for future clinical trials.